Article Details
Retrieved on: 2021-04-29 09:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Merck & Co's Keytruda and Roche's Tecentriq should stay on the market as first-line treatments for bladder cancer, at least until new clinical data ...
Article found on: pharmaphorum.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here